Answers are grounded in this paper and cite their sources.
Coeliac disease (CD) is a growing healthcare concern in many parts of the world. Its clinical presentation is variable, the condition is under-diagnosed and the existing laboratory-based serological tests are underused. Simtomax® is a rapid, point-of-care CD screening test, which—unlike current screening methods—is not invasive, and there are no specific requirements for training in its use, equipment or storage. The test will considerably facilitate screening and allow for faster counselling and treatment. Validation studies confirmed the accuracy of Simtomax® relative to standard ELISA methods and the high negative predictive value and sensitivity observed further supported its use as a screening tool. The budgetary impact of replacing the current CD screening process with the Simtomax® testing kit showed a potential saving to the NHS of over £7 million per year.
No takes yet. Share an insight, caveat, or question.
L Mizen (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: